UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Company as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
InMed Pharmaceuticals Inc. | ||
(Address of Principal Executive Offices) | (Zip Code) |
Company’s telephone number, including
area code: (
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On September 7, 2023, the Company announced that InMed’s Chief Executive Officer, Eric A. Adam’s will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference which takes place September 11-13, 2023 in New York City.
The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
Exhibit No. | Description | |
99.1 | News release, dated September 7, 2023 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INMED PHARMACEUTICALS INC. | ||
Date: September 7, 2023 | By: |
/s/ Eric A Adams |
Eric A Adams | ||
President & CEO |
2
Exhibit 99.1
NASDAQ: INM
Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com |
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
Vancouver, BC – September 7, 2023 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announce that InMed’s Chief Executive Officer, Eric A. Adam’s will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference which takes place September 11-13, 2023 in New York City.
The on-demand presentation by InMed’s Chief Executive Officer, Eric A. Adams, will be made available on September 11, 2023, at 7:00 AM ET. The presentation will be available via webcast archived in the News & Events section of InMed’s Investor Relations website for a period of 90 days.
InMed’s management team will be available for onsite and virtual one-on-one meetings with registered investors during the conference.
About InMed:
InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and https://www.baymedica.com/.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: InMed’s participation in future conferences; being a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
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end
Cover |
Sep. 07, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Sep. 07, 2023 |
Entity File Number | 001-39685 |
Entity Registrant Name | INMED PHARMACEUTICALS INC. |
Entity Central Index Key | 0001728328 |
Entity Tax Identification Number | 98-1428279 |
Entity Incorporation, State or Country Code | A1 |
Entity Address, Address Line One | Suite 310 - 815 W. Hastings Street |
Entity Address, City or Town | Vancouver |
Entity Address, State or Province | BC |
Entity Address, Country | CA |
Entity Address, Postal Zip Code | V6C 1B4 |
City Area Code | 604 |
Local Phone Number | 669-7207 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Shares, no par value |
Trading Symbol | INM |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Z1=G-_D,3)S$&[5F__5+^Y)/D_4$L#!!0 ( &*4
M)U=0]IZD" @ -4@ > 96$Q.#0X-3!E>#DY+3%?:6YM961P:&%R;6$N
M:'1MW5IM<]I($OY.%?^ABZIU)74@@V,[9TQUEI>NI,WFST2*
MU%F#DH<"%".YN*%#44%1RA7<$HN)+RY/B>7RWL>.(V[\E[WBHN>&),-%53YD
ML';6=?-.^S+&H.&_0X8M^I^Q )-IN20H+=SXP$5>V7N_B"=5PTYUAKF1%?-^
MS!-N 8]S)45A!F<5<6[YD"12 _21, J])CJ'>$H#@Z*7CS261]*&1O47$P4]
M[?*@7/JF _C]]?C[1@1V+L60X*ZON3:39((/QU6VD#4HT!$\;H(MN$*Z%J%<
MVM1&T?^@BRJ7OFZCZ$]V4:?3F/_Q?]$T"S:*#H3_1//T8#WHXBY;@W9DY
M/!!:#B][,YTED?_.:54NL?MX^/+')(^S:16DJ[E5Y3G9X9^/6'APQFR.&'F4
MP_GN4&"1=#X-&1(N_?C 9X;Q3?+ 16L"P1Q8Z!@&D$_ 4OC:GVY,VL=Y.:-@
M+&8_J#2@MCMQBB6*$J 9%M;.
%SQ%@.#/,4>*H%ND"%P+D1'^2!=2U8#?5P)Y
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M7#-D#H5SW_I1A ]%0E"_>QEV,_@
MV%'RT%J;KP3[^